US EditionCStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
- Sugemalimab is the first anti-PD-L1 monoclonal antibody approved for gastric or gastroesophageal junction adenocarcinoma, as stated by CStone Pharmaceuticals.
- The GEMSTONE-303 study showed significant improvements in overall survival and progression-free survival using sugemalimab combined with chemotherapy, according to findings published in JAMA.
- Subgroup analyses indicated that sugemalimab plus chemotherapy provided benefits across various PD-L1 expression levels, affirming its efficacy and safety, mentioned by Professor Lin Shen.
- CStone has received multiple approvals for sugemalimab in China and internationally, expanding its market presence and treatment applications.
Insights by Ground AI
Does this summary seem wrong?
50 Articles
50 Articles
All
Left
4
Center
13
Right
5
Coverage Details
Total News Sources50
Leaning Left4Leaning Right5Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 18%
C 59%
R 23%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage